Pfizer (NYSE:PFE) Sets New 12-Month High – Here’s What Happened

Pfizer Inc. (NYSE:PFE) reached a new 52-week high on Tuesday . The stock traded as high as $29.09 and last traded at $28.7470, with a volume of 8392245 shares changing hands. The stock had previously closed at $28.46.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Strong quarterly performance: Pfizer reported earnings and revenue above expectations, with quarterly revenue increasing year over year. The results, along with growth in vaccines and oncology, have helped drive renewed investor interest. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Legal overhang reduced: Pfizer’s reported settlement of more than 6,000 Depo-Provera lawsuits removes some litigation uncertainty and may be viewed favorably by investors. Pfizer Stock Surges to 52-Week Peak Following Strong Q2 Results and Major Legal Settlement
• Positive Sentiment: Pipeline activity: Pfizer has begun a Phase 1 study of asthma candidate PF-08103402. Although early-stage programs are not near-term revenue drivers, the trial provides another potential growth asset as the company works to offset future patent expirations. Pfizer’s New Asthma Candidate PF-08103402 Enters Phase 1
• Neutral Sentiment: Valuation and dividend appeal: A bullish investment case argues that PFE remains attractive below $30 for patient, income-oriented investors, supported by its dividend and long-term recovery potential. Should You Buy Pfizer Stock Below $30?
• Negative Sentiment: Growth concerns persist: Commentary highlights declining core-business revenue and the approaching patent cliff. Pfizer’s AI strategy is viewed as a longer-term promise rather than evidence of immediate earnings growth. Can AI Save Pfizer Stock Before Its Patent Cliff Hits?
• Negative Sentiment: Bearish sentiment remains visible: Jim Cramer declined to recommend Pfizer despite its dividend, while unusually high put-option activity suggests some traders are positioning for downside or hedging near the recent high. Cramer Won’t Recommend Pfizer Even With Its Dividend

Wall Street Analysts Forecast Growth

Several research firms have recently commented on PFE. HSBC downgraded Pfizer from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Weiss Ratings upgraded Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. Wolfe Research restated an “underperform” rating and set a $26.00 target price on shares of Pfizer in a research note on Thursday, May 14th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Finally, JPMorgan Chase & Co. dropped their price target on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $28.28.

Pfizer Stock Up 1.7%

The firm has a market capitalization of $165.42 billion, a PE ratio of 38.19, a P/E/G ratio of 1.92 and a beta of 0.34. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.27 and a quick ratio of 0.96. The company has a 50-day moving average price of $25.79 and a 200 day moving average price of $26.32.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The firm had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the business posted $0.78 earnings per share. The firm’s revenue was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th were given a dividend of $0.43 per share. The ex-dividend date was Friday, July 24th. This represents a $1.72 annualized dividend and a dividend yield of 5.9%. Pfizer’s dividend payout ratio (DPR) is presently 226.32%.

Hedge Funds Weigh In On Pfizer

A number of hedge funds and other institutional investors have recently modified their holdings of PFE. Evolution Wealth Management Inc. lifted its stake in Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 566 shares in the last quarter. Godfrey Financial Associates Inc. bought a new stake in shares of Pfizer in the fourth quarter worth about $26,000. Keb Asset Management LLC bought a new stake in shares of Pfizer in the second quarter worth about $26,000. HFM Investment Advisors LLC lifted its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 427 shares in the last quarter. Finally, Field & Main Bank bought a new position in Pfizer during the second quarter valued at approximately $27,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.